Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.
about
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategiesDoes my patient with a serum monoclonal spike have multiple myeloma?Smoldering multiple myeloma requiring treatment: time for a new definition?Characterization of monoclonal gammopathy in patients with amyotrophic lateral sclerosis.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.Progression of Monoclonal Gammopathy with Undetermined Significance to Multiple Myeloma Diagnosed by Kidney Biopsy: A Case Report.High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression.Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients.[Monoclonal gammopathy of undetermined significance and monoclonal B-lymphocytosis].Will the real myeloma please stand up?How I manage monoclonal gammopathy of undetermined significance.Multiple myeloma
P2860
Q24607241-DC568E07-8EA0-469F-8ED8-2AE60DF9229FQ26821981-8CFCB0FF-5E19-4DCB-9A77-BBDC8A2684A7Q26996579-C5074C24-5291-4E2E-B927-B01ED6F19C61Q30316799-93AE82E9-354D-4D5E-93E0-EBBA89FBAD09Q33695919-825D0DAE-52DC-4A34-B941-9F00CAB83602Q34525834-77D26EB1-7802-4A8D-A099-A28D6A571532Q35132283-B7B35426-A572-40C6-94CE-3D91C9FFEE0BQ36170670-8DE1A2B6-32CE-451D-AED9-FC3C6BA856C4Q36683750-784F820A-35C3-46EC-98B3-7F8A13217052Q36950805-83771841-4232-4E81-8CD5-01B9F4517347Q37582168-E784EC19-04EA-4873-B5EF-05B5B241388DQ37593481-1E9364BC-6E6C-4690-9FE1-DEA179154616Q37795413-741F2A8D-DA2F-4691-A44C-7065D16D10BFQ38114487-19967DDE-E4BE-4A39-B99A-B084ECC381E1Q38199534-CE2E95E2-B4D4-4815-9939-B31B0C0FBD46Q38766508-8EB1E308-D5B7-460A-AAD1-A13CF276B749Q39981858-D68E70C2-3E5A-4E2F-A27E-F073EF8BBFAAQ43704889-D3C632AD-FB25-42C6-AA1C-35FBF26D6289Q43817358-025D6ED5-A526-4D0D-82D9-7CFB4B2C2AE1Q48221793-18315BDA-7338-4E46-80F3-A5A769918280Q56657250-C54A5746-3601-465B-8B61-175DA09E7DE6
P2860
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impact of optimal follow-up of ...... myeloma-related complications.
@ast
Impact of optimal follow-up of ...... myeloma-related complications.
@en
Impact of optimal follow-up of ...... myeloma-related complications.
@nl
type
label
Impact of optimal follow-up of ...... myeloma-related complications.
@ast
Impact of optimal follow-up of ...... myeloma-related complications.
@en
Impact of optimal follow-up of ...... myeloma-related complications.
@nl
prefLabel
Impact of optimal follow-up of ...... myeloma-related complications.
@ast
Impact of optimal follow-up of ...... myeloma-related complications.
@en
Impact of optimal follow-up of ...... myeloma-related complications.
@nl
P2093
P2860
P50
P1433
P1476
Impact of optimal follow-up of ...... myeloma-related complications
@en
P2093
Colin L Colby
Dirk R Larson
Giada Bianchi
Jerry A Katzmann
L Joseph Melton
Robert A Kyle
Shaji Kumar
Terry M Therneau
P2860
P304
2019-25; quiz 2197
P356
10.1182/BLOOD-2010-04-277566
P407
P577
2010-05-21T00:00:00Z